SCHEMBL8317130

SCHEMBL8317130

c1ccc2c(c1)COc1ccccc1C2=C1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 9/20 0.47
HRH4 Q9H3N8 6/20 0.47
KMT2A Q03164 3/20 0.44
SETD7 Q8WTS6 2/20 0.44
LMNA P02545 3/20 0.43
JAK2 O60674 1/20 0.43
HTT P42858 1/20 0.43
HTR2C P28335 3/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
KCNH2 Q12809 4/20 0.40
ALDH1A1 P00352 3/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
HTR2B P41595 3/20 0.38
CHRM2 P08172 2/20 0.38
CHRM4 P08173 2/20 0.38
HTR1A P08908 2/20 0.38
CHRM5 P08912 2/20 0.38
ADRA2A P08913 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31350805 1.00 HRH1 (0.47) HRH1HRH4KMT2ASETD7LMNA
Hydrochloric Acid SCHEMBL9718788 0.98 HRH1 (0.46) HRH1HRH4KMT2ASETD7LMNA
SCHEMBL13870474 0.86 HRH1 (0.53) HRH1HRH4KMT2ASETD7LMNA
SCHEMBL13870498 0.86 KCNH2 (0.46) HRH1HRH4KMT2ASETD7LMNA
SCHEMBL12065133 0.84 KCNH2 (0.47) HRH1HRH4KMT2ALMNAJAK2
SCHEMBL12065131 0.84 HRH1 (0.51) HRH1HRH4KMT2ALMNAJAK2
SCHEMBL13888615 0.83 KCNH2 (0.44) HRH1HRH4KMT2ASETD7LMNA
SCHEMBL3044086 0.82 HRH1 (0.52) HRH1HRH4KMT2ASETD7LMNA
SCHEMBL13870536 0.81 HRH1 (0.40) HRH1HRH4LMNAJAK2HTT
SCHEMBL5905789 0.81 SETD7 (0.59) HRH1HRH4KMT2ASETD7LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 US disclosed
WO-2011148888-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST あすか製薬株式会社 (JP) 2011-12-01 WO disclosed
US-7524864-B2 Methods of treating sleep disorders HYPNION, INC. (US) 2009-04-28 US disclosed
US-7524864-B2 Methods of treating sleep disorders HYPNION, INC. (US) 2009-04-28 US disclosed
US-7482460-B2 Doxepin analogs and methods of use thereof HYPNION, INC. (US) 2009-01-27 US disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 US disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 US disclosed
EP-0536419-B1 TRICYCLIC TRIAZOLE DERIVATIVES, PRODUCTION AND USE THEREOF TORAY INDUSTRIES (JP) 1999-10-13 EP disclosed
EP-0536419-A1 TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 1993-04-14 EP disclosed
US-5095022-A Antiallergens HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1992-03-10 US disclosed
EP-0406739-A2 Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1991-01-09 EP disclosed
US-4912222-A Antihistamines related to cyproheptadine FISONS CORPORATION (US) 1990-03-27 US disclosed
WO-1989012443-A1 NOVEL DIBENZO-CYCLOHEPTENYL, -CYCLOHEPTYL AND -OXEPINYL AMINES HAVING ANTIHISTAMINIC PROPERTIES FISONS CORPORATION (US) 1989-12-28 WO disclosed
EP-0347123-A2 Dibenzo-cycloheptenyl, -cycloheptyl and -oxepinyl amines having antihistaminic properties FISONS CORPORATION (US) 1989-12-20 EP disclosed
US-4072756-A Tricyclo piperidino ketones and soporific compositions thereof SANDOZ LTD. (CH) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 HRH1 3/4885HRH4 2/4885KMT2A 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.